Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDRAE VANDROSS

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1205079373
CMS profile
2789901
Location
AUSTIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$385.16

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $385.16 4

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Exelixis Inc. $162.17 1
Mirati Therapeutics, Inc. $109.34 1
ADC Therapeutics America, Inc. $95.79 1
Deciphera Pharmaceuticals Inc. $17.86 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDRAE VANDROSS

NPI 1205079373 · CMS profile ID 2789901

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

AUSTIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1205079373?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDRAE VANDROSS, NPI 1205079373, CMS profile ID 2789901. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205079373?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ANDRAE VANDROSS, NPI 1205079373, CMS profile ID 2789901. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205079373?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ANDRAE VANDROSS, NPI 1205079373, CMS profile ID 2789901, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1205079373?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $385.16 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Deciphera Pharmaceuticals Inc. $17.8606/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053721931 CMS
Exelixis Inc. $162.1706/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044564159 CMS
Mirati Therapeutics, Inc. $109.3404/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058005541 CMS
ADC Therapeutics America, Inc. $95.7903/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053791479 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $175.94 3
PY2020 $44.69 3
PY2021 $107.19 6
PY2022 $430.20 11
PY2023 $385.16 4
PY2024 $1,083.01 10
PY2025 $3,168.19 7

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $874,433.33 238
PY2024 Principal investigator $413,921.09 482
PY2023 Principal investigator $420,700.05 715
PY2022 Principal investigator $499,990.99 172
PY2021 Principal investigator $187,276.47 47

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

715 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $781.50 12/31/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998414805
Principal investigator 1 Exelixis Inc. $85.05 12/27/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937953
Principal investigator 1 Exelixis Inc. $99.90 12/27/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937961
Principal investigator 1 Deciphera Pharmaceuticals Inc. $685.00 12/22/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739913
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 12/18/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739863
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,870.00 12/18/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739865
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,143.00 12/18/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739873
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,438.00 12/18/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739875
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,034.00 12/18/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739877
Principal investigator 1 ABBVIE INC. $685.00 12/13/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998411647
Principal investigator 1 ABBVIE INC. $485.00 12/13/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998411649
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,082.70 12/06/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739767
Principal investigator 1 ABBVIE INC. $500.00 11/28/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998409045
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,506.00 11/22/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739737
Principal investigator 1 Deciphera Pharmaceuticals Inc. $297.00 11/22/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739739
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,768.00 11/22/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739743
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,506.00 11/22/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739745
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 11/22/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739747
Principal investigator 1 Deciphera Pharmaceuticals Inc. $14,483.19 11/22/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1060359497
Principal investigator 1 Exelixis Inc. $482.63 11/14/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937937
Principal investigator 1 Exelixis Inc. $482.63 11/14/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937945
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,700.00 11/03/2023 Non-covered Recipient Entity
New Experimental Therapeutics of Austin - NEXT Oncology
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1040391981
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,240.00 11/03/2023 Non-covered Recipient Entity
New Experimental Therapeutics of Austin - NEXT Oncology
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1040391997
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,300.00 11/03/2023 Non-covered Recipient Entity
New Experimental Therapeutics of Austin - NEXT Oncology
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1040392013
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $41,337.45 11/03/2023 Non-covered Recipient Entity
New Experimental Therapeutics of Austin - NEXT Oncology
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1040392029
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $5,714.00 11/03/2023 Non-covered Recipient Entity
New Experimental Therapeutics of Austin - NEXT Oncology
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1040392045
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,755.00 11/01/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739103
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,418.00 11/01/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739107
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,748.00 11/01/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739113
Principal investigator 1 Deciphera Pharmaceuticals Inc. $668.00 11/01/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739119
Principal investigator 1 Deciphera Pharmaceuticals Inc. $946.00 11/01/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739125
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,438.00 11/01/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739131
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,755.00 11/01/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739137
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,541.00 11/01/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739143
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,418.00 11/01/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739149
Principal investigator 1 Deciphera Pharmaceuticals Inc. $608.00 11/01/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739153
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,992.00 11/01/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739189
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,260.00 11/01/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739201
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,315.00 11/01/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739205
Principal investigator 1 ABBVIE INC. $75.00 10/27/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998405409
Principal investigator 1 ABBVIE INC. $3,255.00 10/27/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998405411
Principal investigator 1 ABBVIE INC. $4,326.08 10/27/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998405413
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,300.00 10/27/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1040392061
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,143.00 10/20/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739007
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,768.00 10/20/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739013
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 10/20/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739019
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,438.00 10/20/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739025
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,034.00 10/20/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739031
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,870.00 10/20/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739037
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,143.00 10/20/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739041
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 10/20/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053739047
Principal investigator 1 Exelixis Inc. $775.00 10/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937913
Principal investigator 1 Exelixis Inc. $431.00 10/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937921
Principal investigator 1 Exelixis Inc. $775.00 10/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937929
Principal investigator 1 Merck Sharp & Dohme LLC $28,400.00 10/06/2023 Non-covered Recipient Entity
NEXT Austin
A Phase 1,1b Dose Escalation,Expansion Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1042566901
Principal investigator 1 ABBVIE INC. $270.00 10/05/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998402849
Principal investigator 1 ABBVIE INC. $3,523.50 10/05/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998402851
Principal investigator 1 Deciphera Pharmaceuticals Inc. $931.50 10/04/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053738387
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,196.10 10/04/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053738393
Principal investigator 1 Deciphera Pharmaceuticals Inc. $782.60 10/04/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053738405
Principal investigator 1 Deciphera Pharmaceuticals Inc. $455.00 10/04/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053738411
Principal investigator 1 ABBVIE INC. $600.00 10/02/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998401609
Principal investigator 1 ABBVIE INC. $4,313.25 10/02/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998401611
Principal investigator 1 Exelixis Inc. $365.00 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937743
Principal investigator 1 Exelixis Inc. $275.00 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937751
Principal investigator 1 Exelixis Inc. $450.00 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937759
Principal investigator 1 Exelixis Inc. $350.00 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937767
Principal investigator 1 Exelixis Inc. $315.00 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937775
Principal investigator 1 Exelixis Inc. $775.00 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937783
Principal investigator 1 Exelixis Inc. $59.40 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937791
Principal investigator 1 Exelixis Inc. $450.00 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937799
Principal investigator 1 Exelixis Inc. $350.00 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937807
Principal investigator 1 Exelixis Inc. $315.00 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937815
Principal investigator 1 Exelixis Inc. $482.63 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937823
Principal investigator 1 Exelixis Inc. $50.00 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937829
Principal investigator 1 Exelixis Inc. $1,250.00 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937839
Principal investigator 1 Exelixis Inc. $500.00 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937847
Principal investigator 1 Exelixis Inc. $500.00 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937855
Principal investigator 1 Exelixis Inc. $775.00 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937863
Principal investigator 1 Exelixis Inc. $412.86 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937871
Principal investigator 1 Exelixis Inc. $482.63 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937879
Principal investigator 1 Exelixis Inc. $482.63 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937887
Principal investigator 1 Exelixis Inc. $482.63 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937895
Principal investigator 1 Exelixis Inc. $482.63 08/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041937903
Principal investigator 1 ABBVIE INC. $1,452.60 07/25/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998392379
Principal investigator 1 ABBVIE INC. $1,452.60 07/25/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998392381
Principal investigator 1 ABBVIE INC. $5,134.05 07/25/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998392383
Principal investigator 1 ABBVIE INC. $1,601.10 07/25/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998392473
Principal investigator 1 ABBVIE INC. $3,523.50 07/25/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998392475
Principal investigator 1 ABBVIE INC. $4,313.25 07/25/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998392477
Principal investigator 1 ABBVIE INC. $2,214.00 07/25/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998392479
Principal investigator 1 ABBVIE INC. $4,735.80 07/25/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998392481
Principal investigator 1 ABBVIE INC. $1,601.10 07/25/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998392485
Principal investigator 1 Deciphera Pharmaceuticals Inc. $7,552.00 07/25/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1060359471
Principal investigator 1 Exelixis Inc. $58.05 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934305
Principal investigator 1 Exelixis Inc. $99.90 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934329
Principal investigator 1 Exelixis Inc. $58.05 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934367
Principal investigator 1 Exelixis Inc. $58.05 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934375
Principal investigator 1 Exelixis Inc. $59.40 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934383
Principal investigator 1 Exelixis Inc. $99.90 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934389
Principal investigator 1 Exelixis Inc. $51.30 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934397
Principal investigator 1 Exelixis Inc. $51.30 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934403
Principal investigator 1 Exelixis Inc. $58.05 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934413
Principal investigator 1 Exelixis Inc. $67.50 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934419
Principal investigator 1 Exelixis Inc. $67.50 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934427
Principal investigator 1 Exelixis Inc. $59.40 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934435
Principal investigator 1 Exelixis Inc. $49.95 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934443
Principal investigator 1 Exelixis Inc. $85.05 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934451
Principal investigator 1 Exelixis Inc. $85.05 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934459
Principal investigator 1 Exelixis Inc. $99.90 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934467
Principal investigator 1 Exelixis Inc. $51.30 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934475
Principal investigator 1 Exelixis Inc. $51.30 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934483
Principal investigator 1 Exelixis Inc. $58.05 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934491
Principal investigator 1 Exelixis Inc. $67.50 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934499
Principal investigator 1 Exelixis Inc. $59.40 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934507
Principal investigator 1 Exelixis Inc. $59.40 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934515
Principal investigator 1 Exelixis Inc. $49.95 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934523
Principal investigator 1 Exelixis Inc. $49.95 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934531
Principal investigator 1 Exelixis Inc. $85.05 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934539
Principal investigator 1 Exelixis Inc. $99.90 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934545
Principal investigator 1 Exelixis Inc. $99.90 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934553
Principal investigator 1 Exelixis Inc. $51.30 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934561
Principal investigator 1 Exelixis Inc. $58.05 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934569
Principal investigator 1 Exelixis Inc. $58.05 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934577
Principal investigator 1 Exelixis Inc. $59.40 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934585
Principal investigator 1 Exelixis Inc. $49.95 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934593
Principal investigator 1 Exelixis Inc. $99.90 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934601
Principal investigator 1 Exelixis Inc. $3,871.80 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934609
Principal investigator 1 Exelixis Inc. $3,871.80 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934615
Principal investigator 1 Exelixis Inc. $51.30 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934625
Principal investigator 1 Exelixis Inc. $58.05 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934631
Principal investigator 1 Exelixis Inc. $67.50 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934639
Principal investigator 1 Exelixis Inc. $67.50 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934647
Principal investigator 1 Exelixis Inc. $59.40 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934655
Principal investigator 1 Exelixis Inc. $49.95 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934663
Principal investigator 1 Exelixis Inc. $85.05 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934671
Principal investigator 1 Exelixis Inc. $85.05 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934677
Principal investigator 1 Exelixis Inc. $99.90 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934685
Principal investigator 1 Exelixis Inc. $51.30 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934693
Principal investigator 1 Exelixis Inc. $51.30 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934699
Principal investigator 1 Exelixis Inc. $49.95 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934707
Principal investigator 1 Exelixis Inc. $97.20 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934715
Principal investigator 1 Exelixis Inc. $97.20 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934723
Principal investigator 1 Exelixis Inc. $97.20 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934731
Principal investigator 1 Exelixis Inc. $97.20 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934739
Principal investigator 1 Exelixis Inc. $97.20 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934747
Principal investigator 1 Exelixis Inc. $97.20 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934755
Principal investigator 1 Exelixis Inc. $97.20 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934761
Principal investigator 1 Exelixis Inc. $97.20 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934769
Principal investigator 1 Exelixis Inc. $27.00 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934869
Principal investigator 1 Exelixis Inc. $27.00 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934877
Principal investigator 1 Exelixis Inc. $27.00 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934887
Principal investigator 1 Exelixis Inc. $27.00 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934895
Principal investigator 1 Exelixis Inc. $27.00 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934903
Principal investigator 1 Exelixis Inc. $27.00 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934911
Principal investigator 1 Exelixis Inc. $27.00 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934919
Principal investigator 1 Exelixis Inc. $27.00 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934927
Principal investigator 1 Exelixis Inc. $67.50 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935621
Principal investigator 1 Exelixis Inc. $85.05 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935861
Principal investigator 1 Exelixis Inc. $99.90 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935869
Principal investigator 1 Exelixis Inc. $3,871.80 06/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935895
Principal investigator 1 ABBVIE INC. $270.00 05/22/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998384101
Principal investigator 1 ABBVIE INC. $2,744.55 05/22/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998384103
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $750.00 05/19/2023 Non-covered Recipient Entity
New Experimental Therapeutics of Austin - NEXT Oncology
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1040391967
Principal investigator 1 Exelixis Inc. $2,173.50 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931635
Principal investigator 1 Exelixis Inc. $51.30 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934235
Principal investigator 1 Exelixis Inc. $58.05 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934243
Principal investigator 1 Exelixis Inc. $58.05 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934251
Principal investigator 1 Exelixis Inc. $85.05 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934275
Principal investigator 1 Exelixis Inc. $59.40 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934291
Principal investigator 1 Exelixis Inc. $99.90 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934299
Principal investigator 1 Exelixis Inc. $51.30 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934313
Principal investigator 1 Exelixis Inc. $49.95 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934321
Principal investigator 1 Exelixis Inc. $27.00 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934337
Principal investigator 1 Exelixis Inc. $27.00 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934345
Principal investigator 1 Exelixis Inc. $99.90 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934351
Principal investigator 1 Exelixis Inc. $99.90 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934359
Principal investigator 1 Exelixis Inc. $97.20 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934843
Principal investigator 1 Exelixis Inc. $97.20 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934851
Principal investigator 1 Exelixis Inc. $97.20 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934861
Principal investigator 1 Exelixis Inc. $79.65 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934934
Principal investigator 1 Exelixis Inc. $67.50 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935255
Principal investigator 1 Exelixis Inc. $51.30 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935653
Principal investigator 1 Exelixis Inc. $58.05 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935661
Principal investigator 1 Exelixis Inc. $58.05 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935669
Principal investigator 1 Exelixis Inc. $2,173.50 05/15/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935853
Principal investigator 1 ABBVIE INC. $1,452.60 04/21/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998379275
Principal investigator 1 ABBVIE INC. $2,744.55 04/21/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998379277
Principal investigator 1 ABBVIE INC. $1,601.10 04/21/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998379279
Principal investigator 1 ABBVIE INC. $270.00 04/21/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998379281
Principal investigator 1 ABBVIE INC. $4,313.25 04/21/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998379287
Principal investigator 1 ABBVIE INC. $2,632.50 04/21/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998379289
Principal investigator 1 ABBVIE INC. $1,601.10 04/21/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998379291
Principal investigator 1 ABBVIE INC. $3,523.50 04/21/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998379293
Principal investigator 1 ABBVIE INC. $1,452.60 04/21/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998379295
Principal investigator 1 ABBVIE INC. $5,134.05 04/21/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998379299
Principal investigator 1 ABBVIE INC. $4,735.80 04/21/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998379301
Principal investigator 1 Exelixis Inc. $1,290.60 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931581
Principal investigator 1 Exelixis Inc. $4,105.35 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931589
Principal investigator 1 Exelixis Inc. $3,871.80 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931597
Principal investigator 1 Exelixis Inc. $1,310.85 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931605
Principal investigator 1 Exelixis Inc. $472.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931611
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931621
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931627
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931643
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931652
Principal investigator 1 Exelixis Inc. $200.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931657
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931665
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931673
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931679
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931687
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931695
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931703
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931711
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931717
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931725
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931731
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931741
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931749
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931755
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931765
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931771
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931777
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931787
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931793
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931801
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931809
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931817
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931825
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931833
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931841
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931847
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931855
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931863
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931871
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931879
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931887
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931893
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931903
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931911
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931919
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931927
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931934
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931943
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931949
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931957
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931965
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931973
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931981
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931989
Principal investigator 1 Exelixis Inc. $79.65 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041931997
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932005
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932011
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932019
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932027
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932035
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932043
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932051
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932059
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932067
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932075
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932083
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932089
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932099
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932107
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932113
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932121
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932129
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932137
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932143
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932153
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932161
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932169
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932177
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932186
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932193
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932201
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932209
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932217
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932225
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932233
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932241
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932249
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932257
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932265
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932273
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932281
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932289
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932297
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932305
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932313
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932321
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932331
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932337
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932347
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932355
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932363
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932371
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932379
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932387
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932395
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932403
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932411
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932419
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932427
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932435
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932443
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932451
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932459
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932467
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932475
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932483
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932491
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932499
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932507
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932515
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932523
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932531
Principal investigator 1 Exelixis Inc. $79.65 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932539
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932545
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932553
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932561
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932569
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932577
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932583
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932591
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932599
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932609
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932617
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932625
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932633
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932641
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932649
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932655
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932663
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932671
Principal investigator 1 Exelixis Inc. $79.65 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932677
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932685
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932693
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932701
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932709
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932719
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932727
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932735
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932743
Principal investigator 1 Exelixis Inc. $79.65 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932751
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932759
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932767
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932775
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932783
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932791
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932797
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932807
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932815
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932821
Principal investigator 1 Exelixis Inc. $79.65 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932829
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932837
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932845
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932853
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932861
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932871
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932879
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932887
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932895
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932901
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932909
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932917
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932925
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932933
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932941
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932949
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932959
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932967
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932973
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932981
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932989
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041932997
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933005
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933013
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933021
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933029
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933037
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933045
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933053
Principal investigator 1 Exelixis Inc. $198.45 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933061
Principal investigator 1 Exelixis Inc. $52.65 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933069
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933077
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933085
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933095
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933101
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933111
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933117
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933125
Principal investigator 1 Exelixis Inc. $198.45 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933133
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933141
Principal investigator 1 Exelixis Inc. $52.65 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933149
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933157
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933165
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933173
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933181
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933189
Principal investigator 1 Exelixis Inc. $90.45 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933197
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933205
Principal investigator 1 Exelixis Inc. $68.85 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933213
Principal investigator 1 Exelixis Inc. $198.45 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933219
Principal investigator 1 Exelixis Inc. $198.45 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933227
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933235
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933243
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933251
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933261
Principal investigator 1 Exelixis Inc. $90.45 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933269
Principal investigator 1 Exelixis Inc. $68.85 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933277
Principal investigator 1 Exelixis Inc. $198.45 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933285
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933291
Principal investigator 1 Exelixis Inc. $52.65 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933299
Principal investigator 1 Exelixis Inc. $31.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933305
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933315
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933323
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933331
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933339
Principal investigator 1 Exelixis Inc. $90.45 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933347
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933355
Principal investigator 1 Exelixis Inc. $198.45 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933361
Principal investigator 1 Exelixis Inc. $198.45 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933369
Principal investigator 1 Exelixis Inc. $52.65 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933381
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933389
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933397
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933403
Principal investigator 1 Exelixis Inc. $90.45 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933411
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933421
Principal investigator 1 Exelixis Inc. $198.45 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933427
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933435
Principal investigator 1 Exelixis Inc. $31.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933443
Principal investigator 1 Exelixis Inc. $31.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933451
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933459
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933467
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933475
Principal investigator 1 Exelixis Inc. $90.45 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933483
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933491
Principal investigator 1 Exelixis Inc. $198.45 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933499
Principal investigator 1 Exelixis Inc. $52.65 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933507
Principal investigator 1 Exelixis Inc. $31.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933515
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933523
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933531
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933539
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933547
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933553
Principal investigator 1 Exelixis Inc. $79.65 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933563
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933571
Principal investigator 1 Exelixis Inc. $76.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933579
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933587
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933595
Principal investigator 1 Exelixis Inc. $31.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933601
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933609
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933617
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933625
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933635
Principal investigator 1 Exelixis Inc. $90.45 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933643
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933651
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933659
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933667
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933675
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933683
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933691
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933699
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933707
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933715
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933723
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933731
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933737
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933747
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933755
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933763
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933771
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933779
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933787
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933795
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933803
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933811
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933819
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933825
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933833
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933841
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933849
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933857
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933865
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933873
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933881
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933889
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933897
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933903
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933911
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933919
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933929
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933935
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933943
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933951
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933959
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933967
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933975
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933985
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041933993
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934001
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934009
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934017
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934025
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934031
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934039
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934047
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934055
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934063
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934071
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934079
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934087
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934095
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934103
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934107
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934115
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934125
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934133
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934139
Principal investigator 1 Exelixis Inc. $79.65 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934149
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934155
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934163
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934171
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934177
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934185
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934193
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934201
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934211
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934217
Principal investigator 1 Exelixis Inc. $79.65 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934227
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934259
Principal investigator 1 Exelixis Inc. $49.95 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934267
Principal investigator 1 Exelixis Inc. $67.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934283
Principal investigator 1 Exelixis Inc. $236.25 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934777
Principal investigator 1 Exelixis Inc. $236.25 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934787
Principal investigator 1 Exelixis Inc. $236.25 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934795
Principal investigator 1 Exelixis Inc. $236.25 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934803
Principal investigator 1 Exelixis Inc. $236.25 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934811
Principal investigator 1 Exelixis Inc. $236.25 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934819
Principal investigator 1 Exelixis Inc. $236.25 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934827
Principal investigator 1 Exelixis Inc. $236.25 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934835
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934941
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934949
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934957
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934965
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934975
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934983
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934991
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041934999
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935007
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935015
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935023
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935031
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935035
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935043
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935051
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935059
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935065
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935073
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935081
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935089
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935097
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935105
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935115
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935125
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935133
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935141
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935149
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935157
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935165
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935173
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935179
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935187
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935195
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935203
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935211
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935217
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935225
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935233
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935241
Principal investigator 1 Exelixis Inc. $85.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935247
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935265
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935273
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935281
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935289
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935297
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935305
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935313
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935321
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935329
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935337
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935345
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935353
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935363
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935371
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935379
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935385
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935393
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935401
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935409
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935415
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935425
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935433
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935441
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935447
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935455
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935461
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935469
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935477
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935487
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935491
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935499
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935507
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935515
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935523
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935531
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935536
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935543
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935551
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935559
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935567
Principal investigator 1 Exelixis Inc. $59.40 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935575
Principal investigator 1 Exelixis Inc. $472.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935583
Principal investigator 1 Exelixis Inc. $472.50 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935591
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935600
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935607
Principal investigator 1 Exelixis Inc. $27.00 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935615
Principal investigator 1 Exelixis Inc. $68.85 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935629
Principal investigator 1 Exelixis Inc. $68.85 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935637
Principal investigator 1 Exelixis Inc. $68.85 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935645
Principal investigator 1 Exelixis Inc. $198.45 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935677
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935685
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935693
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935701
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935713
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935721
Principal investigator 1 Exelixis Inc. $97.20 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935729
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935737
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935745
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935753
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935759
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935767
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935775
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935783
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935791
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935799
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935807
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935815
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935823
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935831
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935839
Principal investigator 1 Exelixis Inc. $51.30 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935847
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935877
Principal investigator 1 Exelixis Inc. $99.90 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935885
Principal investigator 1 Exelixis Inc. $1,175.85 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935903
Principal investigator 1 Exelixis Inc. $1,175.85 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935911
Principal investigator 1 Exelixis Inc. $1,175.85 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935919
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935927
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935935
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935943
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935951
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935959
Principal investigator 1 Exelixis Inc. $58.05 04/17/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935967
Principal investigator 1 Deciphera Pharmaceuticals Inc. $12,852.00 04/13/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053728917
Principal investigator 1 Deciphera Pharmaceuticals Inc. $14,483.19 04/05/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053728859
Principal investigator 1 ABBVIE INC. $2,671.99 03/23/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998375631
Principal investigator 1 Deciphera Pharmaceuticals Inc. $13,974.00 03/17/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053728285
Principal investigator 1 ABBVIE INC. $300.00 03/15/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998373977
Principal investigator 1 Exelixis Inc. $315.00 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935991
Principal investigator 1 Exelixis Inc. $235.00 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935999
Principal investigator 1 Exelixis Inc. $235.00 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936007
Principal investigator 1 Exelixis Inc. $350.00 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936015
Principal investigator 1 Exelixis Inc. $1,175.85 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936031
Principal investigator 1 Exelixis Inc. $50.00 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936047
Principal investigator 1 Exelixis Inc. $50.00 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936055
Principal investigator 1 Exelixis Inc. $50.00 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936063
Principal investigator 1 Exelixis Inc. $1,907.72 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936071
Principal investigator 1 Exelixis Inc. $500.00 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936087
Principal investigator 1 Exelixis Inc. $500.00 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936095
Principal investigator 1 Exelixis Inc. $500.00 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936103
Principal investigator 1 Exelixis Inc. $500.00 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936111
Principal investigator 1 Exelixis Inc. $500.00 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936119
Principal investigator 1 Exelixis Inc. $250.00 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936127
Principal investigator 1 Exelixis Inc. $250.00 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936135
Principal investigator 1 Exelixis Inc. $282.02 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936143
Principal investigator 1 Exelixis Inc. $1,443.09 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936151
Principal investigator 1 Exelixis Inc. $1,290.60 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936177
Principal investigator 1 Exelixis Inc. $275.00 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936187
Principal investigator 1 Exelixis Inc. $275.00 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936193
Principal investigator 1 Exelixis Inc. $275.00 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936201
Principal investigator 1 Exelixis Inc. $275.00 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936207
Principal investigator 1 Exelixis Inc. $450.00 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936225
Principal investigator 1 Exelixis Inc. $365.00 03/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936233
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,448.15 02/17/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053728235
Principal investigator 1 Deciphera Pharmaceuticals Inc. $59.00 02/17/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053728237
Principal investigator 1 ABBVIE INC. $1,700.00 02/16/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998371101
Principal investigator 1 Exelixis Inc. $600.00 02/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935975
Principal investigator 1 Exelixis Inc. $600.00 02/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041935983
Principal investigator 1 Exelixis Inc. $3,740.85 02/13/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936039
Principal investigator 1 ABBVIE INC. $500.00 01/30/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998367545
Principal investigator 1 ABBVIE INC. $3,844.80 01/23/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998367107
Principal investigator 1 ABBVIE INC. $3,523.50 01/23/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998367109
Principal investigator 1 ABBVIE INC. $1,452.60 01/23/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998367111
Principal investigator 1 ABBVIE INC. $1,452.60 01/23/2023 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998367113
Principal investigator 1 Deciphera Pharmaceuticals Inc. $563.05 01/20/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053728097
Principal investigator 1 Deciphera Pharmaceuticals Inc. $455.00 01/20/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053728099
Principal investigator 1 Deciphera Pharmaceuticals Inc. $59.00 01/20/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053728101
Principal investigator 1 Deciphera Pharmaceuticals Inc. $676.35 01/20/2023 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1053728105
Principal investigator 1 Exelixis Inc. $500.00 01/16/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936023
Principal investigator 1 Exelixis Inc. $3,315.60 01/16/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936079
Principal investigator 1 Exelixis Inc. $1,040.85 01/16/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936159
Principal investigator 1 Exelixis Inc. $275.00 01/16/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936167
Principal investigator 1 Exelixis Inc. $1,175.85 01/16/2023 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC.
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1041936217